Patent-pending NR, NRH, NMN/NMNH, and BioPeak®-NAD technologies designed to improve selected active-ingredient delivery, support differentiated premium product lines, and create strategic value across science-driven longevity portfolios.

PATENT-PENDING NAD+ & LONGEVITY TECHNOLOGY PORTFOLIO

STRATEGIC PARTNERSHIPS

Two Distinct NR Technologies. Next-Generation NRH. Advanced Bioavailability Platforms.

RejuvaTech LLC develops filed intellectual-property platforms for next-generation NAD+ precursors and premium longevity ingredients. Our portfolio includes two separately filed NR technologies—RiboGEN®-BT and RiboGEN®-D—together with stabilized NRH and BioPeak® advanced delivery platforms.

We are evaluating qualified global manufacturing, licensing and commercialization partners.

CORE TECHNOLOGY PLATFORMS

RiboGEN®-BT — Distinct Next-Generation NR Technology

Patent-pending stabilized amorphous / low-crystallinity NR platform designed to create a differentiated alternative to conventional commodity NR.

RiboGEN®-D — Distinct Anhydrous NRCl Technology

A separately filed patent-pending crystalline NR chloride platform providing an independent second NR development and commercialization pathway.

RiboGEN® II — Stabilized NRH Platform

Protected next-generation NRH technologies addressing stability, manufacturing and practical commercialization challenges.

BioPeak®-NAD — Advanced Bioavailability Platform

Patent-pending delivery architecture for selected NAD+ precursors and high-value wellness actives.

BioPeak®-TR — Advanced Triterpenoid Platform

Technology for premium triterpenoid, beauty-from-within, skin and healthy-aging applications.


RiboGEN®-BT and RiboGEN®-D are separate filed inventions—not two versions of the same NR technology.

STRATEGIC MANUFACTURING & COMMERCIALIZATION

GLOBAL PARTNERSHIPS FOR PROTECTED LONGEVITY TECHNOLOGIES

RejuvaTech is evaluating qualified global partners to manufacture, license, and commercialize its patent-pending longevity technologies across ingredient, finished-product, private-label, and premium wellness markets.

We are particularly interested in companies with established capabilities in NAD-related manufacturing, GMP scale-up, international ingredient sales, formulation support, and global customer development.

Qualified partners may receive staged, NDA-protected access to patent summaries, technical packages, formulation architecture, analytical data, and commercialization plans. Detailed process know-how is provided only through defined development, manufacturing, and licensing agreements.


Our objective is to combine RejuvaTech-owned IP with experienced manufacturing and global marketing partners to create differentiated premium product platforms.



NEXT-GENERATION NAD+ PRECURSOR PLATFORM

RiboGEN® II — PROTECTED STABILIZED NRH TECHNOLOGY

NRH is a reduced form of nicotinamide riboside with significant potential as a next-generation NAD+ precursor. However, commercial development has historically been limited by chemical instability, oxidation and moisture sensitivity, powder-handling challenges, and difficulty maintaining reproducible material during manufacturing and storage.

RejuvaTech has developed two separately filed patent-pending NRH technologies designed to address both sides of commercialization: stabilized NRH manufacture and composition, and delivery/use of stabilized NRH in premium NAD+ products.

The objective is not another commodity NAD ingredient. RiboGEN® II is being developed as a protected, commercially practical NRH platform capable of supporting GMP scale-up, global ingredient supply, and differentiated finished-product formulations.

BioPeak®-NAD can provide an additional premium delivery layer for selected RiboGEN® II applications, creating a broader protected product architecture for qualified partners.

Detailed chemistry, manufacturing pathways, stability targets, formulation architecture, and supporting technical data are available only through NDA-protected staged diligence.


Strategic objective: establish a protected next-generation NAD+ precursor category beyond conventional NR and NMN.

PREMIUM TRITERPENOID & BOTANICAL PLATFORM

BIOPEAK®-TR — PROTECTED DELIVERY TECHNOLOGY FOR HIGH-VALUE TRITERPENOIDS

Triterpenoids and related botanical actives have significant potential across healthy aging, skin and hair, beauty-from-within, mobility, and premium wellness, but many are commercially limited by poor solubility, inconsistent absorption, formulation difficulty, and inefficient delivery.

BioPeak®-TR is RejuvaTech’s patent-pending platform designed to improve the practical delivery and commercial value of selected high-value triterpenoid and botanical ingredients.

The platform is intended to help qualified manufacturing partners create differentiated premium ingredients and finished products rather than compete only with conventional commodity extracts.

Potential applications include:

  • Cycloastragenol and related Astragalus-derived actives
  • Centella asiatica triterpenoids
  • Oleanolic and related triterpenoid compounds
  • Skin and scalp/hair applications
  • Beauty-from-within products
  • Joint, mobility, and healthy-aging formulations

BioPeak®-TR can be integrated into ingredient manufacturing, formulation, private-label, and branded finished-product programs, allowing qualified partners to commercialize the technology across multiple product categories and international markets.

Detailed formulation architecture, ingredient-specific applications, manufacturing integration, supporting data, and development targets are available through NDA-protected staged diligence.

Strategic objective: convert high-value triterpenoid actives from conventional ingredients into protected premium product platforms.

FLEXIBLE STRATEGIC PARTNERSHIP MODELS

MULTIPLE PATHS TO GLOBAL COMMERCIALIZATION

RejuvaTech works with qualified ingredient manufacturers and global commercialization partners through flexible licensing, manufacturing, and market-development structures tailored to each technology and product category.

Potential partnership models may include:

  • Authorized manufacturing of protected RejuvaTech ingredients
  • Exclusive or field-limited licensing by product, market, or territory
  • BioPeak® enhancement of ingredients a partner already manufactures and sells
  • Co-branded or private-label premium products
  • Global ingredient marketing through existing customer networks and international trade shows
  • Joint technical validation and commercialization planning

RejuvaTech’s objective is to combine protected IP with an experienced manufacturer’s production capabilities, existing customer relationships, and global sales infrastructure.

Detailed licensing structures, technical packages, formulas, manufacturing information, and commercial terms are provided through NDA-protected staged diligence.

Strategic objective: allow each partner to commercialize RejuvaTech technology in the way that best fits its manufacturing strengths and existing global customer base.